MA-IBASIS
18.5.2021 07:02:13 CEST | Business Wire | Press release
iBASIS , the leading provider of communications solutions for operators and digital players worldwide, today announced the launch of iBASIS Carrier Voice for Teamwork , enabling carriers such as China Telecom Europe (CTE), a leading provider to European multinationals, to serve Enterprise customers with much needed cloud-based PBX functionality for their collaboration platforms.
With the massive shift toward Microsoft Teams triggered by COVID-19, carriers have an immediate opportunity to seize new Enterprise revenues by delivering a proven solution to bring voice to Microsoft Teams. iBASIS Carrier Voice for Teamwork™ provides global service availability, from and to the cloud via 2-way PSTN numbers, enabling native voice service in 60+ markets for global termination to help carriers respond to their local Enterprise demand. Carriers have the option to keep their own numbers to avoid porting or leverage iBASIS for local numbers.
The solution is built on iBASIS’ established wholesale leadership to drive voice capabilities for Microsoft Teams and deliver proven performance ensuring that carriers like CTE gain extremely quick time-to-market with its pay-as-you-go model, flexible pricing plans, easy configuration, and self-service portal.
”iBASIS Carrier Voice for Teamwork provides China Telecom Europe (CTE) with voice for Microsoft Teams to respond to and support their Enterprise customers with more effective collaboration across the globe ,” says Edwin van Ierland, Chief Commercial Officer and Chief Operating Officer at iBASIS. “Leveraging our reach, scale, independence, and leading technology partnerships, CTE was able to rapidly roll out easy-to-deploy capabilities to meet fast-moving market conditions. ”
“Our value proposition at China Telecom Europe (CTE) is differentiated by our holistic ICT approach, ” adds Nathan Li, Deputy Director, Voice & Messaging, China Telecom Europe. “The iBASIS Carrier Voice for Teamwork™ provides us with a proven, highly flexible solution with a customer-friendly commercial structure that helps us to quickly adapt to new opportunities for business growth. We trust iBASIS to continue delivering on quality, opportunity, and partnership. ”
iBASIS plans to broaden Carrier Voice for Teamwork to other tools, like Slack, Zoom, and WebEx. The solution is part of iBASIS’ larger Carrier Cloud Communications portfolio, which includes cloud numbering solutions, international numbers, global voice termination, and Communications Platform as a Service (CPaaS). iBASIS continues to enable carriers with opportunities to regain control and outperform throughout the large-scale transformations of their Enterprise customers.
Please visit us online for more information about iBASIS Carrier Voice for Teamwork .
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global , iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, and Top 3 LTE IPX vendor with 700+ LTE destinations. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com .
ABOUT CHINA TELECOM (EUROPE) LTD.
China Telecom (Europe) Ltd . (CTE) provides integrated telecommunications and technology services as local, regional, and global solutions for Chinese, Asian, and European multinational corporations. CTE’s unrivaled knowledge of the Chinese market and regional offices across Europe make CTE an ideal partner for European and Asian businesses looking to work in China and Asia. Please visit us online for more information at chinatelecomeurope.com .
iBASIS® and other marks as indicated are the trademarks or registered trademarks of iBASIS, Inc. or other companies in the United States and other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005948/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom